Lead Sponsor

Eisai Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Males and females 18 years or older with a clinical diagnosis of mild-to-moderate plaque-type psoriasis for ≥12 months prior to screening
•Female participants postmenopausal \>1 year or surgically sterile
•Two representative and similar target lesions for the condition, each of 15-25 centimeters squared (cm\^2), up to 50 cm\^2 in surface area
•Target lesion severity score of 4-8 on a scale of 0 to 12, where, in the opinion of the Investigator, 0 equals no evidence of disease and 12 equals severe induration, erythema, scaling, and pruritus
•Prescription medications, if applicable, for chronic conditions allowed but must be on a stable regimen prior to and during the study; this is also applicable for dietary supplements and over-the-counter (OTC) drugs
•Participants able and willing to give informed consent

•Use of any, concomitant, topical treatment for psoriasis, excluding emollients
•Use of any, concomitant, systemic treatment for psoriasis, including ultraviolet radiation (UVR) light
•Evidence of significant hepatic, gastrointestinal, renal, respiratory, endocrine, hematological, neurological, psychiatric, musculoskeletal, rheumatologic, or cardiovascular system abnormalities
•Evidence of any clinically significant deviation from normal with respect to medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), or clinical laboratory determinations. If any participant has an abnormal clinical laboratory test finding that meets specified criteria, that participant will be re-tested by repeated blood draw and clinical laboratory assessment. If the abnormal test finding is confirmed, the participant will be excluded from the study.

Related studies

NCT07337434 · Chronic Plaque Psoriasis

NCT06591273 · Moderate to Severe Chronic Plaque Psoriasis

NCT03410992 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, and more

NCT03536884 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis

NCT03370133 · Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, and more

Paired-Comparison Study Evaluating the Efficacy and Safety of E6201 Versus Vehicle for the Treatment of Plaque-Type Psoriasis